5AM Ventures

Investment Thesis

5AM Ventures focuses on early-stage life sciences companies developing breakthrough therapeutics and precision medicine solutions. They take a hands-on company-building approach, often working with founders from inception through clinical development. The firm specializes in identifying transformative science and building companies around novel platforms.

Team

Partners / Managing Directors

• Kush M Parmar, MD, PhD - Managing Partner
• Andy J. Schwab - Managing Partner
• Michael Calore - Partner, Head of Investor Relations
• John Kelly - Partner, Chief Financial Officer & Chief Operating Officer
• Deborah Palestrant, PhD - Partner, Executive Chair, 4:59 Initiative
• Paul A. Stone, JD - Partner, Chief Legal Officer
• Anna Yaeger - Partner, Head of Public Equities
• Scott M. Rocklage, PhD - Founding Partner
• John D. Diekman, PhD - Founding Partner

Focus Areas

• Precision Medicine
• Biological Engineering
• Novel Therapeutic Platforms
• Genetic Medicines
• Cell Therapy
• Oncology
• Rare Diseases

Notable Exits

• Flexion Therapeutics - Acquired (2021, by Pacira BioSciences for $630M)
• Codiak BioSciences - IPO (2020, NASDAQ: CDAK)
• Agios Pharmaceuticals - IPO (2013, NASDAQ: AGIO)
• Foundation Medicine - Acquired (2018, by Roche for $2.4B)

Sources

• https://www.5amventures.com
• https://www.5amventures.com/team
• https://www.crunchbase.com/organization/5am-ventures
• https://pitchbook.com/profiles/5am-ventures